New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...
U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Differences emerged as to which participants were more likely to cut back on drinking after starting medication. For example, ...
Martin Makary, President-elect Trump’s pick to run the U.S. Food and Drug Administration ... in the middle of a fight ...
"Influencers on social media platforms like TikTok and Instagram only show the good things that happen and say 'look how good ...
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback